Research and Markets: Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Pipeline Review, H2 2014 - 27 Companies & 49 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/9hxbmd/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Involved in Therapeutics Development

  • DURECT Corporation
  • Eli Lilly and Company
  • Taisho Pharmaceutical Co., Ltd.
  • NeuroDerm Ltd.
  • Takeda Pharmaceutical Company Limited
  • Richter Gedeon Nyrt.
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Shire Plc
  • Vernalis plc
  • Collegium Pharmaceutical, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Arbor Pharmaceuticals, LLC.
  • Curemark, LLC
  • Supernus Pharmaceuticals, Inc.
  • Intra-Cellular Therapies, Inc.
  • Tris Pharma, Inc.
  • Neos Therapeutics, Inc.
  • KemPharm, Inc.
  • Otsuka Holdings Co., Ltd.
  • Reviva Pharmaceuticals Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Mnemosyne Pharmaceuticals, Inc.
  • Alcobra Ltd
  • Sunovion Pharmaceuticals Inc.
  • Signature Therapeutics, Inc
  • P2D Bioscience

For more information visit http://www.researchandmarkets.com/research/9hxbmd/attention_deficit

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System